Zydus Lifesciences Limited
ZYDUSLIFE
Classement en actions
#1753
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Prix de l'action
$12.30
Capitalisation boursière
$12.27B
Changement (1 jour)
0.04%
Changement (1 an)
8.30%
Pays
IN
Échange Zydus Lifesciences Limited (ZYDUSLIFE)
Catégorie
Healthcare
EPS pour Zydus Lifesciences Limited (ZYDUSLIFE)
EPS au June 2026 TTM : $0.50
Selon les derniers rapports financiers et le cours de l'action de Zydus Lifesciences Limited, l’EPS actuel de la société (TTM) est de $0.50. À la fin de 2024, la société avait un EPS de $0.45 une augmentation par rapport à celui de 2023, qui était de $0.24.
Historique de l'EPS de Zydus Lifesciences Limited de 2004 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $0.50 | -6.57% |
| 2025 | $0.53 | 15.66% |
| 2024 | $0.45 | 93.04% |
| 2023 | $0.24 | -18.37% |
| 2022 | $0.29 | -1.80% |
| 2021 | $0.29 | 92.66% |
| 2020 | $0.15 | -41.37% |
| 2019 | $0.26 | -3.38% |
| 2018 | $0.27 | 19.91% |
| 2017 | $0.22 | -21.26% |
| 2016 | $0.29 | 58.30% |
| 2015 | $0.18 | 37.48% |
| 2014 | $0.13 | 11.58% |
| 2013 | $0.12 | -6.53% |
| 2012 | $0.13 | -19.49% |
| 2011 | $0.16 | 112.82% |
| 2010 | $0.07 | 16.35% |
| 2009 | $0.06 | -7.62% |
| 2008 | $0.07 | 19.23% |
| 2007 | $0.06 | -98.42% |
| 2006 | $3.63 | 6,117.81% |
| 2005 | $0.06 | -10.43% |
| 2004 | $0.07 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 12.34% |
IN
|
